136 related articles for article (PubMed ID: 26059878)
1. Resolution of paraneoplastic immune thrombocytopenia following everolimus treatment for metastatic renal cell carcinoma.
Zheng S; Chan H; Epstein RJ; Joseph JE
Intern Med J; 2015 Jun; 45(6):666-9. PubMed ID: 26059878
[TBL] [Abstract][Full Text] [Related]
2. Immunomodulatory effects of everolimus in a long responsive patient with metastatic renal cell carcinoma.
Thiery-Vuillemin A; Laheurte C; Mansi L; Royer B; Pivot X; Borg C; Adotevi O
J Immunother; 2014 Jan; 37(1):51-4. PubMed ID: 24316556
[TBL] [Abstract][Full Text] [Related]
3. Exceptional response to everolimus in a novel tuberous sclerosis complex-2 mutation-associated metastatic renal-cell carcinoma.
Alsidawi S; Kasi PM
Cold Spring Harb Mol Case Stud; 2018 Apr; 4(2):. PubMed ID: 29610387
[TBL] [Abstract][Full Text] [Related]
4. Complete response in metastatic renal cell carcinoma after radiotherapy and everolimus: a clinical case and review of the literature.
Detti B; Francolini G; Becherini C; Olmetto E; Giacomelli I; Scartoni D; Greto D; Baldazzi V; Simontacchi G; Meattini I; Livi L
J Chemother; 2016 Oct; 28(5):432-4. PubMed ID: 27376403
[TBL] [Abstract][Full Text] [Related]
5. Lenvatinib/everolimus improves survival better than everolimus alone in metastatic renal cell cancer.
Clin Adv Hematol Oncol; 2015 Aug; 13(8):512-3. PubMed ID: 26351813
[No Abstract] [Full Text] [Related]
6. Renal cell carcinoma associated with idiopathic thrombocytopenic purpura.
Xie X; Wang N; Xiang J; He H; Wang X; Wang Y
Int J Immunopathol Pharmacol; 2020; 34():2058738420931619. PubMed ID: 32567409
[TBL] [Abstract][Full Text] [Related]
7. Everolimus in the treatment of renal cell carcinoma and neuroendocrine tumors.
Chan HY; Grossman AB; Bukowski RM
Adv Ther; 2010 Aug; 27(8):495-511. PubMed ID: 20623346
[TBL] [Abstract][Full Text] [Related]
8. REACT expanded-access program in patients with metastatic renal cell carcinoma: real-world data from a European subanalysis.
Bracarda S; Rottey S; Bahl A; Eichelberg C; Mellado B; Mangel L; Cattaneo A; Panneerselvam A; Grünwald V
Future Oncol; 2015; 11(21):2893-903. PubMed ID: 26376939
[TBL] [Abstract][Full Text] [Related]
9. Clinical prognostic factors associated with outcome in patients with renal cell cancer with prior tyrosine kinase inhibitors or immunotherapy treated with everolimus.
Amato RJ; Flaherty A; Zhang Y; Ouyang F; Mohlere V
Urol Oncol; 2014 Apr; 32(3):345-54. PubMed ID: 24321256
[TBL] [Abstract][Full Text] [Related]
10. Changes in the diffusion capacity for carbon monoxide and the development of non-infectious pneumonitis in patients with metastatic renal cell carcinoma treated with everolimus.
Park K; Kim HJ; Lee JL; Lee KH; Jeong IG; Song C; Hong BS; Hong J; Kim CS; Ahn H
Anticancer Res; 2014 Oct; 34(10):5723-8. PubMed ID: 25275080
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and Safety of Sequential Use of Everolimus in Patients With Metastatic Renal Cell Carcinoma Previously Treated With Bevacizumab With or Without Interferon Therapy: Results From the European AVATOR Study.
Thiery-Vuillemin A; Theodore C; Jacobasch L; Schmitz J; Papandreou C; Guillot A; Emmanouilides C; Slimane K; Kelkouli N; Kim S; Nguyen Tan Hon T
Clin Genitourin Cancer; 2015 Jun; 13(3):231-8. PubMed ID: 25456838
[TBL] [Abstract][Full Text] [Related]
12. A randomized phase 2 study of MK-2206 versus everolimus in refractory renal cell carcinoma.
Jonasch E; Hasanov E; Corn PG; Moss T; Shaw KR; Stovall S; Marcott V; Gan B; Bird S; Wang X; Do KA; Altamirano PF; Zurita AJ; Doyle LA; Lara PN; Tannir NM
Ann Oncol; 2017 Apr; 28(4):804-808. PubMed ID: 28049139
[TBL] [Abstract][Full Text] [Related]
13. Immune thrombocytopenia during interferon-alfa therapy for renal cell carcinoma.
Akamatsu S; Asazuma A; Kanamaru S; Takenawa J; Soeda A
Hinyokika Kiyo; 2006 Oct; 52(10):789-92. PubMed ID: 17131869
[TBL] [Abstract][Full Text] [Related]
14. Everolimus for patients with metastatic renal cell carcinoma refractory to anti-VEGF therapy: results of a pooled analysis of non-interventional studies.
Albiges L; Kube U; Eymard JC; Schmidinger M; Bamias A; Kelkouli N; Mraz B; Florini S; Guderian G; Cattaneo A; Bergmann L
Eur J Cancer; 2015 Nov; 51(16):2368-74. PubMed ID: 26276039
[TBL] [Abstract][Full Text] [Related]
15. An international expanded-access programme of everolimus: addressing safety and efficacy in patients with metastatic renal cell carcinoma who progress after initial vascular endothelial growth factor receptor-tyrosine kinase inhibitor therapy.
Grünwald V; Karakiewicz PI; Bavbek SE; Miller K; Machiels JP; Lee SH; Larkin J; Bono P; Rha SY; Castellano D; Blank CU; Knox JJ; Hawkins R; Anak O; Rosamilia M; Booth J; Pirotta N; Bodrogi I;
Eur J Cancer; 2012 Feb; 48(3):324-32. PubMed ID: 21803569
[TBL] [Abstract][Full Text] [Related]
16. Immune thrombocytopenic purpura in a patient with renal cell carcinoma.
Cho EJ; Lee HJ; Park KU; Kim UY; Lee HJ; Bang SM
Korean J Intern Med; 2014 Sep; 29(5):671-4. PubMed ID: 25228845
[No Abstract] [Full Text] [Related]
17. [A case of renal cell carcinoma associated with idiopathic thrombocytopenic purpura].
Yoshinaga A; Hayashi T; Ohno R; Yoshida S; Ishii N; Terao T; Watanabe T; Yamada T
Hinyokika Kiyo; 2005 Jun; 51(6):377-80. PubMed ID: 16050475
[TBL] [Abstract][Full Text] [Related]
18. Resection of bulky chromophobe renal cell carcinoma resolved severe idiopathic thrombocytopenic purpura: A case report.
Maekawa S; Nagata M; Watanabe H; Nozaki K; Takahashi A; Minowada S; Homma Y
Int J Urol; 2015 Dec; 22(12):1167-9. PubMed ID: 26354444
[TBL] [Abstract][Full Text] [Related]
19. [A Case of Renal Cell Carcinoma with High Everolimus Blood Concentrations and Hyperglycemia Due to Everolimus-Induced Hepatic Dysfunction].
Takasaki S; Kikuchi M; Kawasaki Y; Ito A; Arai Y; Yamaguchi H; Mano N
Gan To Kagaku Ryoho; 2017 Jan; 44(1):87-89. PubMed ID: 28174388
[TBL] [Abstract][Full Text] [Related]
20. [Spontaneous Remission of Everolimus-Induced Interstitial Lung Disease in Metastatic Renal Cell Carcinoma : An Autopsy Case Report].
Kurokawa M; Naito S; Ichiyanagi O; Kabasawa T; Kurota Y; Sakurai T; Nishida H; Kawazoe H; Kato T; Nagaoka A; Yamakawa M; Tsuchiya N
Hinyokika Kiyo; 2017 Sep; 63(9):377-380. PubMed ID: 28992668
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
